An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2
Status:
Completed
Trial end date:
2018-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on
glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2
(T2DM) at Month 6.